CURRENT MEASURES AGAINST OPHTHALMIC COMPLICATIONS OF DIABETES MELLITUS - A SHORT REVIEW

Authors

  • MANORMA Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • RUPA MAZUMDER Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • ANJNA RANI Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • RAJAT BUDHORI Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India
  • AYUSHI KAUSHIK Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park-2, Institutional Area, Greater Noida, Uttar Pradesh 201306, India

DOI:

https://doi.org/10.22159/ijap.2021v13i6.42876

Keywords:

Ophthalmic formulations, diabetes mellitus, ocular complications, cataract, glaucoma, diabetic retinopathy, macular oedema

Abstract

Diabetes mellitus (DM) is a metabolic disorder, whose prevalence is predicted to rise shortly. The present review focuses on the various ocular complications associated with DM, and the various ophthalmic formulation approaches developed to treat the same. Diabetic macular edema (DME), diabetic retinopathy, cataracts, and glaucoma are some of the major vision-threatening complications linked to DM. The ocular route of drug delivery has undergone several advancements in recent decades, the introduction of various novel drug delivery systems (DDS), various modifications in the existing formulation approaches, development of custom-designed personalized medications, being some of the major developments introduced in the field of ocular drug delivery. Due to the application of state-of-the-art technologies in the field of innovations related to ocular DDS, patients have been immensely benefited by the current modes of ocular treatment imparting fewer side effects, enhanced penetration, sustained drug effect, and so on. The present review includes and emphasizes the gradual development that has occurred from the conventional ophthalmic dosage forms to the currently reported novel ocular drug delivery approaches along with the related patents and clinical research works.

Downloads

Download data is not yet available.

References

Kelkar A, Kelkar J, Mehta H, Amoaku W. Cataracts surgery in diabetes mellitus: A systematic review. Indian J Ophthalmol. 2018 Oct;66(10):1401-1410.

Kharroubi AT, Darwish HM. Diabetes mellitus: The epidemic of the century. World J Diabetes. 2015 Jun 25;6(6):850-67.

Endris T, Worede A, Asmelash D. Prevalence of Diabetes Mellitus, Prediabetes and Its Associated Factors in Dessie Town, Northeast Ethiopia: A Community-Based Study. Diabetes Metab Syndr Obes. 2019 Dec 31;12:2799-809.

Henriques J, Vaz-Pereira S, Nascimento J, Rosa PC. Doença Ocular Diabética [Diabetic eye disease]. Acta Med Port. 2015 Jan-Feb;28(1):107-13.

Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes. 2015 Feb 15;6(1):92-108.

Wong TY, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology. 2008 Nov;115(11):1869-75.

Kaur A, Gupta V, Christopher AF, Malik MA, Bansal P. Nutraceuticals in the prevention of cataracts - An evidence-based approach. Saudi J Ophthalmol. 2017 Jan-Mar;31(1):30-37.

Peterson SR, Silva PA, Murtha TJ, Sun JK. Cataract Surgery in Patients with Diabetes: Management Strategies. Semin Ophthalmol. 2018;33(1):75-82.

Hamid S, Gul A, Hamid Q. Relationship of cytokines and AGE products in diabetic and non-diabetic patients with cataract. Int J Health Sci. 2016 Oct;10(4):507-515.

Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016 Apr 15;93(8):668-74. PMID: 27175839.

Kiziltoprak H, Tekin K, Inanc M, Goker YS. Cataracts in diabetes mellitus. World J Diabetes. 2019 Mar 15;10(3):140-53.

Chiou SH, Chang CJ, Chou CK, Hsu WM, Liu JH, Chiang CH. Increased nitric oxide levels in aqueous humor of diabetic patients with neovascular glaucoma. Diabetes Care. 1999 May;22(5):861-2.

Zghal I, Jeddi A, Hadj Alouane WB, Malouche N, Ayed S, Gaigi S. Glaucome primitif à angle ouvert et diabète [Primary open-angle glaucoma and diabetes]. Tunis Med. 2000 Aug-Sep;78(8-9):518-21.

Sanders RJ, Wilson MR. Diabetes-related eye disorders. J Natl Med Assoc. 1993 Feb;85(2):104-8.

Stahl A. The Diagnosis , and Treatment of Age-Related Macular Degeneration. Dtsch Arztebl Int. 2020 Jul 20;117(29-30):513-20.

Jung HA, Islam MD, Kwon YS, Jin SE, Son YK, Park JJ, Sohn HS, Choi JS. Extraction, and identification of three major aldose reductase inhibitors from Artemisia montana. Food Chem Toxicol. 2011 Feb;49(2):376-84.

Thiagarajan G, Venu T, Balasubramanian D. Approaches to relieve the burden of cataracts blindness through natural antioxidants: use of Ashwagandha (Withania somnifera). Curr. Sci. 2003;85:1065-71.

Kinoshita JH. A thirty year journey in the polyol pathway. Exp Eye Res. 1990 Jun;50(6):567-73.

Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications, and Non-diabetic Diseases. Mini Rev Med Chem. 2016;16(2):120-62.

Julius, A., and W. Hopper. Inhibition of advanced glycation end-product formation by quercetin, and catechin: An alternative therapy for treating diabetic complications. Asian J Pharm Clin Res. 2017 Nov;10(11):173-6.

Dixit BL, Balendiran GK, Watowich SJ, Srivastava S, Ramana KV, Petrash JM, Bhatnagar A, Srivastava SK. Kinetic, and structural characterization of the glutathione-binding site of aldose reductase. J Biol Chem. 2000 Jul 14;275(28):21587-95.

Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ. Aldose reductase enzyme, and its implication to major health problems of the 21(st) century. Curr Med Chem. 2009;16(6):734-52.

Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes, and beyond. Circ Res. 2003 Dec 12;93(12):1159-69.

Srivastava S, Ramana KV, Tammali R, Srivastava SK, Bhatnagar A. Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes. 2006 Apr;55(4):901-10.

Ramana KV, Friedrich B, Srivastava S, Bhatnagar A, Srivastava SK. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes. 2004 Nov;53(11):2910-20.

Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005 Jan;67(1):3-21.

Stitt AW. The maillard reaction in eye diseases. Ann N Y Acad Sci. 2005 Jun;1043:582-97.

Ornek K, Karel F, Büyükbingöl Z. May nitric oxide molecule have a role in the pathogenesis of human cataracts? Exp Eye Res. 2003 Jan;76(1):23-7.

Nagaraj RH, Linetsky M, Stitt AW. The pathogenic role of Maillard reaction in the aging eye. Amino Acids. 2012 Apr;42(4):1205-20.

Agarwal R, Gupta SK, Agarwal P, Saxena R, Agrawal SS. Current concepts in the pathophysiology of glaucoma. Indian J Ophthalmol. 2009 Jul-Aug;57(4):257-66.

Lee DA, Higginbotham EJ. Glaucoma, and its treatment: a review. Am J Health Syst Pharm. 2005 Apr 1;62(7):691-9.

CD Dimitrioua, and DC. Pathophysiology of glaucoma. Future Medicine Ltd. 2013.

Kaushik S, P, andav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med. 2003 Jan-Mar;49(1):90-5.

Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma, and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995 Apr;36(5):774-86.

Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci. 2014 Aug 14;55(8):5005-15.

Pacher P, Beckman JS, Liaudet L. Nitric oxide, and peroxynitrite in health, and disease. Physiol Rev. 2007 Jan;87(1):315-424.

Wong VH, Bui BV, Vingrys AJ. Clinical, and experimental links between diabetes, and glaucoma. Clin Exp Optom. 2011 Jan;94(1):4-23.

Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms, and neuroprotective strategies. Ophthalmol Clin North Am. 2005 Sep;18(3):383-95.

Pendergast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol. 1998 Jun;9(3):71-5.

Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors, and angiogenesis in eye disease. Prog Retin Eye Res. 2003 Jan;22(1):1-29.

Josh Z, Yuen OD. Reconsider your approach to diabetic retionopathy. Rev. Optom. 2015 Jun: 28-9

Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP. Prevention of leukostasis, and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10836-41.

Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM. Advanced glycation end products, and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005 Jul;15(7):16R-28R.

Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy, and diabetic macular edema disease severity scales. Ophthalmology. 2003 Sep;110(9):1677-82.

Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011 Sep;30(5):343-58.

Wilkinson-Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: roles of angiotensin II, and aldosterone. Peptides. 2012 Jul;36(1):142-50.

Gao S, Qin T, Liu Z, Caceres MA, Ronchi CF, Chen CY, Yeum KJ, Taylor A, Blumberg JB, Liu Y, Shang F. Lutein, and zeaxanthin supplementation reduces H2O2-induced oxidative damage in human lens epithelial cells. Mol Vis. 2011;17:3180-90.

Bruno G, Costantino L, Curinga C, Maccari R, Monforte F, Nicoló F, Ottanà R, Vigorita MG. Synthesis, and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg Med Chem. 2002 Apr;10(4):1077-84.

Pegklidou K, Nicolaou I, Demopoulos VJ. Nutritional overview on the management of type 2 diabetes, and the prevention of its complications. Curr Diabetes Rev. 2010 Nov;6(6):400-9.

Chatzopoulou M, Alexiou P, Kotsampasakou E, Demopoulos VJ. Novel aldose reductase inhibitors: a patent survey (2006--present). Expert Opin Ther Pat. 2012 Nov;22(11):1303-23.

Leuenberger PM. Cataractse diabétique et flavonoïdes (premiers résultats) [Diabetic cataracts , and flavonoids (first results) (author's transl)]. Klin Monbl Augenheilkd. 1978 Apr;172(4):460-2.

Huang R, Shi F, Lei T, Song Y, Hughes CL, Liu G. Effect of the isoflavone genistein against galactose-induced cataracts in rats. Exp Biol Med (Maywood). 2007 Jan;232(1):118-25.

Moghaddam MS, Kumar PA, Reddy GB, Ghole VS. Effect of Diabecon on sugar-induced lens opacity in organ culture: mechanism of action. J Ethnopharmacol. 2005 Feb 28;97(2):397-403.

Matsumoto T, Ono Y, Kuromiya A, Toyosawa K, Ueda Y, Bril V. Long-term treatment with ranirestat (AS-3201), a potent aldose reductase inhibitor, suppresses diabetic neuropathy, and cataracts formation in rats. J Pharmacol Sci. 2008 Jul;107(3):340-8.

Mucke HAM, Mucke E, Mucke PM. Aldose Reductase Inhibitors for Diabetic Cataracts: A Study of Disclosure Patterns in Patents, and Peer Review Papers. Ophthalmol Res: Int. J 2014 Jan;2(3):137-49.

Jaiswal S, Ss T, Mishra S. Neuroprotective effect of epalrestat on memory impairment in streptozotocin-induced type-2 diabetic rats using different behavioral models. Asian J Pharm Clin Res. 2018 Jan 1:411-5.

Suzen S, Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. Curr Med Chem. 2003 Aug;10(15):1329-52.

Kojima M, Sun L, Hata I, Sakamoto Y, Sasaki H, Sasaki K. Efficacy of alpha-lipoic acid against diabetic cataracts in rat. Jpn J Ophthalmol. 2007 Jan-Feb;51(1):10-3.

Durukan AH, Evereklioglu C, Hurmeric V, Kerimoglu H, Erdurman C, Bayraktar MZ, Mumcuoglu T. Ingestion of IH636 grape seed proanthocyanidin extract to prevent selenite-induced oxidative stress in experimental cataracts. J Cataracts Refract Surg. 2006 Jun;32(6):1041-5.

Biswas S, Harris F, Singh J, Phoenix D. Role of calpains in diabetes mellitus-induced cataractogenesis: a mini review. Mol Cell Biochem. 2004 Jun;261(1-2):151-9.

McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969 Nov 25;244(22):6049-55.

Yan Q, Liu JP, Li DW. Apoptosis in lens development, and pathology. Differentiation. 2006 Jun;74(5):195-211.

Saelens X, Festjens N, V, ande Walle L, van Gurp M, van Loo G, V, andenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004 Apr 12;23(16):2861-74.

Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun. 1992;17(4):221-37.

Doganay S, Borazan M, Iraz M, Cigremis Y. The effect of resveratrol in experimental cataracts model formed by sodium selenite. Curr Eye Res. 2006 Feb;31(2):147-53.

Papucci L, Schiavone N, Witort E, Donnini M, Lapucci A, Tempestini A, Formigli L, Zecchi-Orlandini S, Orlandini G, Carella G, Brancato R, Capaccioli S. Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J Biol Chem. 2003 Jul 25;278(30):28220-8.

McCarthy S, Somayajulu M, Sikorska M, Borowy-Borowski H, Pandey S. Paraquat induces oxidative stress, and neuronal cell death; neuroprotection by water-soluble Coenzyme Q10. Toxicol Appl Pharmacol. 2004 Nov 15;201(1):21-31.

Giacco F, Brownlee M. Oxidative stress, and diabetic complications. Circ Res. 2010 Oct 29;107(9):1058-70.

Monnier VM, Cerami A. Non-enzymatic glycosylation, and browning of proteins in diabetes. Clin Endocrinol Metab. 1982 Jul;11(2):431-52.

Clifford MN. Chlorogenic acids, and other cinnamates–nature, occurrence, dietary burden, absorption, and metabolism. J Sci Food Agar. 2007;80:1033- 43.

Morimitsu Y, Yoshida K, Esaki S, Hirota A. Protein glycation inhibitors from thyme (Thymus vulgaris). Biosci Biotechnol Biochem. 1995 Nov;59(11):2018-21.

Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: a review article. J Ophthalmic Vis Res. 2008 Jan;3(1):52-65.

Schmidl D, Schmetterer L, Garhöfer G, Popa-Cherecheanu A. Pharmacotherapy of glaucoma. J Ocul Pharmacol Ther. 2015 Mar;31(2):63-77.

Arthur S, Cantor LB. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res. 2011 Sep;93(3):271-83.

Toris CB, Koepsell SA, Yablonski ME, Camras CB. Aqueous humor dynamics in ocular hypertensive patients. J Glaucoma. 2002 Jun;11(3):253-8.

Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol. 2005 Jun;89(6):758-63.

Grieshaber MC, Flammer J. Is the medication used to achieve the target intraocular pressure in glaucoma therapy of relevance?--an exemplary analysis on the basis of two beta-blockers. Prog Retin Eye Res. 2010 Jan;29(1):79-93.

Pfeiffer N, Lamparter J, Gericke A, Grus FH, Hoffmann EM, Wahl J. Neuroprotection of medical IOP-lowering therapy. Cell Tissue Res. 2013 Aug;353(2):245-51.

Sambhara D, Aref AA. Glaucoma management: relative value, and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43.

Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm. 2002 Nov 6;248(1-2):1-14.

Alagöz N, Tellioglu A, Bektasoglu DL, Yasar T, Basgil Pasaoglu I, Altan AC, Solmaz B, Basarır B. Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice. J Ocul Pharmacol Ther. 2020 Dec;36(10):747-53.

Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S53-S64.

Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012 Apr-Jun;58(2):132-9.

Al Rashaed S, Arevalo JF. Combined therapy for diabetic macular edema. Middle East Afr J Ophthalmol. 2013 Oct-Dec;20(4):315-20.

Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthalmol. 2010 Jul;94(7):858-63.

Daull P, Paterson CA, Kuppermann BD, Garrigue JS. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. J Ocul Pharmacol Ther. 2013 Mar;29(2):258-69.

Fung WE. The national, prospective, randomized vitrectomy study for chronic aphakic cystoid macular edema. Progress report, and comparison between the control, and nonrandomized groups. Surv Ophthalmol. 1984 May;28 Suppl:569-75.

Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, Taylor HR, Welborn TA, Zimmet PZ; AusDiab Study Group. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003 Jun;26(6):1731-7.

Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 2005 Feb;28(2):445-7.

Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery, and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May;3(5):391-400.

Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):943-56.

Matsumiya W, Honda S, Otsuka K, Miki A, Nagai T, Imai H, Kusuhara S, Nakamura M. Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up. Ophthalmologica. 2015 Jun;234(1):33-9.

Siegel AB, Goyal A, Salomao M, Wang S, Lee V, Hsu C, Rodriguez R, Hershman DL, Brown RS Jr, Neugut AI, Emond J, Kato T, Samstein B, Faleck D, Karagozian R. Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology. 2015;88(1):57-68.

Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. Suppression, and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol. 2009 Apr;127(4):494-9.

Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97.

Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed , and/or refractory multiple myeloma. Journal of Clinical Oncology. 2015 Mar 1;33(7):732-9.

Halim EM, Mukhopadhyay AK. Effect of Ocimum sanctum (Tulsi), and vitamin E on biochemical parameters, and retinopathy in streptozotocin induced diabetic rats. Indian J Clin Biochem. 2006 Sep;21(2):181-8.

Agrawal SS, Naqvi S, Gupta SK, Srivastava S. Prevention, and management of diabetic retinopathy in STZ diabetic rats by Tinospora cordifolia, and its molecular mechanisms. Food Chem Toxicol. 2012 Sep;50(9):3126-32.

Wang CZ, Basila D, Aung HH, Mehendale SR, Chang WT, McEntee E, Guan X, Yuan CS. Effects of ganoderma lucidum extract on chemotherapy-induced nausea, and vomiting in a rat model. Am J Chin Med. 2005;33(5):807-15.

Gupta SK, Kumar B, Nag TC, Agrawal SS, Agrawal R, Agrawal P, Saxena R, Srivastava S. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther. 2011 Apr;27(2):123-30.

Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, Dugall M, Cacchio M, Schönlau F. Pycnogenol improves microcirculation, retinal edema, , and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther. 2009 Dec;25(6):537-40.

Kumar VL, Padhy BM. Protective effect of aqueous suspension of dried latex of Calotropis procera against oxidative stress, and renal damage in diabetic rats. Biocell. 2011 Dec;35(3):63-9.

Chen Y, Li XX, Xing NZ, Cao XG. Quercetin inhibits choroidal, and retinal angiogenesis in vitro. Graefes Arch Clin Exp Ophthalmol. 2008 Mar;246(3):373-8.

Nathiya S, Durga M, Devasena T. Quercetin, encapsulated quercetin, and its application-A review. Int. J. Pharm. Pharm. Sci. 2014 Oct;6(10):20-26.

Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1594-9.

Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner EM; UK Prospective Diabetes Study Group. Risks of progression of retinopathy, and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol. 2004 Nov;122(11):1631-40.

Kim JH, Lee BJ, Kim JH, Yu YS, Kim KW. Anti-angiogenic effect of caffeic acid on retinal neovascularization. Vascul Pharmacol. 2009 Oct;51(4):262-7.

Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death, and the development of retinopathy in diabetic rats. Diabetes. 2004 Dec;53(12):3233-8.

Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry. 2003 Jan;62(2):121-5.

Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage, and prevents experimental diabetic retinopathy. Nat Med. 2003 Mar;9(3):294-9.

Moustafa SA. Zinc might protect oxidative changes in the retina, and pancreas at the early stage of diabetic rats. Toxicol Appl Pharmacol. 2004 Dec 1;201(2):149-55.

Lal VK, Verma A. Development, and Evaluation of Ophthalmic Drop, and In-situ Gel from Roots of Boerhaavia diffusa. Journal of Pharmaceutical Research International. 2016 Mar 21:1-20.

Velpandian T, Nirmal J, Gupta P, Vijayakumar AR, Ghose S. Evaluation of calcium dobesilate for its anti-cataracts potential in experimental animal models. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):171-9.

Jonnalagadd VG, Selkar N. Antidiabetic herbal products marketed in India: An update. J Med Plants Stud. 2013;1(6):24-6.

Tanito M, Hara K, Takai Y, Matsuoka Y, Nishimura N, Jansook P, Loftsson T, Stefánsson E, Ohira A. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011 Oct 10;52(11):7944-8.

Mazzolani F, Togni S, Giacomelli L, Eggenhoffner R, Franceschi F. Oral administration of a curcumin-phospholipid formulation (Meriva®) for treatment of chronic diabetic macular edema: a pilot study. Eur Rev Med Pharmacol Sci. 2018 Jun;22(11):3617-3625.

Chae JB, Joe SG, Yang SJ, Lee JY, Sung KR, Kim JY, Kim JG, Yoon YH. Effect of combined cataracts surgery, and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina. 2014 Jan;34(1):149-56.

Ragasa CY, Lorena GS, M, andia EH, Raga DD, Shen CC. Chemical constituents of Abrus precatorius. Amer J Essent Oils Nat Prod. 2013;1(2):7-10.

Radha MH, Laxmipriya NP. Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review. J Tradit Complement Med. 2014 Dec 23;5(1):21-6.

Narayana DB, Durg S, Manohar PR, Mahapatra A, Aramya AR. Chyawanprash: A review of therapeutic benefits as in authoritative texts, and documented clinical literature. J Ethnopharmacol. 2017 Feb 2;197:52-60.

Boti JB, Koukoua G, N'Guessan TY, Casanova J. Chemical variability of Conyza sumatrensis , and Microglossa pyrifolia from Côte d'Ivoire. Flavour , and fragrance journal. 2007 Jan;22(1):27-31.

Kaur IP, Singh M, Kanwar M. Formulation, and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000 Apr 20;199(2):119-27.

Crim N, Velez-Montoya R, Morales-Canton V. Surgical Versus Medical Treatment for Diabetic Macular Edema: A Review. Med Hypothesis Discov Innov Ophthalmol. 2017 Winter;6(4):136-42.

Callanan D, Williams P. Topical nepafenac in the treatment of diabetic macular edema. Clin Ophthalmol. 2008 Dec;2(4):689-92.

Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataracts extraction. Ophthalmology. 1999 Sep;106(9):1656-9.

Kataria P, Katara R, Sahoo PK, Sachdeva S. Dorzolamide in situ Gel Forming System: Characterization, and Evaluation for Glaucoma Treatment. Madridge J Pharm Res. 2017;1:13-21.

Mortazavi SA, Jafariazar Z, Ghadjahani Y, Mahmoodi H, Mehtarpour F. Formulation, and In-vitro Characterization of Sustained Release Matrix Type Ocular Timolol Maleate Mini-Tablet. Iran J Pharm Res. 2014 Winter;13(1):19-27.

Emad Eldeeb A, Salah S, Ghorab M. Proniosomal gel-derived niosomes: an approach to sustain, and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Drug Deliv. 2019 Dec;26(1):509-21.

Dubey A, Prabhu P. Formulation, and evaluation of stimuli-sensitive hydrogels of timolol maleate, and brimonidine tartrate for the treatment of glaucoma. Int J Pharm Investig. 2014 Jul;4(3):112-8.

Alvarez-Rivera F, Concheiro A, Alvarez-Lorenzo C. Epalrestat-loaded silicone hydrogels as contact lenses to address diabetic-eye complications. Eur J Pharm Biopharm. 2018 Jan;122:126-36.

Ali Z, Sharma PK, Warsi MH. Fabrication, and evaluation of ketorolac loaded cubosome for ocular drug delivery. Journal of applied pharmaceutical science. 2016 Sep;6(09):204-8.

Huang J, Peng T, Li Y, Zhan Z, Zeng Y, Huang Y, Pan X, Wu CY, Wu C. Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation. AAPS PharmSciTech. 2017 Nov;18(8):2919-26.

Meza-Rios A, Navarro-Partida J, Armendariz-Borunda J, Santos A. Therapies based on nanoparticles for eye drug delivery. Ophthalmology and therapy. 2020 Sep;9(3):1-4.

Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine. 2012;7:123-31.

Li H, Liu Y, Zhang Y, Fang D, Xu B, Zhang L, Chen T, Ren K, Nie Y, Yao S, Song X. Liposomes as a Novel Ocular Delivery System for Brinzolamide: In Vitro, and In Vivo Studies. AAPS PharmSciTech. 2016 Jun;17(3):710-7.

Katiyar S, Pandit J, Mondal RS, Mishra AK, Chuttani K, Aqil M, Ali A, Sultana Y. In situ gelling dorzolamide loaded chitosan nanoparticles for the treatment of glaucoma. Carbohydr Polym. 2014 Feb 15;102:117-24.

Warsi MH, Anwar M, Garg V, Jain GK, Talegaonkar S, Ahmad FJ, Khar RK. Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study, and evaluation of extended ocular hypotensive effect in rabbits. Colloids Surf B Biointerfaces. 2014 Oct 1;122:423-31.

Jain K, Kumar RS, Sood S, Dhyanandhan G. Betaxolol hydrochloride loaded chitosan nanoparticles for ocular delivery, and their anti-glaucoma efficacy. Curr Drug Deliv. 2013 Oct;10(5):493-9.

Ibrahim MM, Abd-Elgawad AE, Soliman OA, Jablonski MM. Novel topical ophthalmic formulations for management of glaucoma. Pharm Res. 2013 Nov;30(11):2818-31.

Wang F, Chen L, Jiang S, He J, Zhang X, Peng J, Xu Q, Li R. Optimization of methazolamide-loaded solid lipid nanoparticles for ophthalmic delivery using Box-Behnken design. J Liposome Res. 2014 Sep;24(3):171-81.

El-Salamouni NS, Farid RM, El-Kamel AH, El-Gamal SS. Effect of sterilization on the physical stability of brimonidine-loaded solid lipid nanoparticles, and nanostructured lipid carriers. Int J Pharm. 2015 Dec 30;496(2):976-83.

Leonardi A, Bucolo C, Drago F, Salomone S, Pignatello R. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int J Pharm. 2015 Jan 15;478(1):180-86.

Wang F, Chen L, Zhang D, Jiang S, Shi K, Huang Y, Li R, Xu Q. Methazolamide-loaded solid lipid nanoparticles modified with low-molecular weight chitosan for the treatment of glaucoma: in vitro and in vivo study. J Drug Target. 2014 Nov;22(9):849-58.

Fahmy HM, Saad EA, Sabra NM, El-Gohary AA, Mohamed FF, Gaber MH. Treatment merits of Latanoprost/Thymoquinone–Encapsulated liposome for glaucomatus rabbits. International journal of pharmaceutics. 2018 Sep 5;548(1):597-608.

Mokhtar Ibrahim M, Tawfique SA, Mahdy MM. Liposomal diltiazem HCl as ocular drug delivery system for glaucoma. Drug Dev Ind Pharm. 2014 Jun;40(6):765-73.

Yu S, Wang QM, Wang X, Liu D, Zhang W, Ye T, Yang X, Pan W. Liposome incorporated ion sensitive in situ gels for ophthalmic delivery of timolol maleate. Int J Pharm. 2015 Mar 1;480(1-2):128-36.

Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development, and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014 Mar 12;53:10-6.

Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation, and in vitro/in vivo evaluation. AAPS PharmSciTech. 2011 Dec;12(4):1335-47.

Fulgêncio Gde O, Viana FA, Ribeiro RR, Yoshida MI, Faraco AG, Cunha-Júnior Ada S. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J Ocul Pharmacol Ther. 2012 Aug;28(4):350-8.

Kashiwagi K, Ito K, Haniuda H, Ohtsubo S, Takeoka S. Development of latanoprost-loaded biodegradable nanosheet as a new drug delivery system for glaucoma. Invest Ophthalmol Vis Sci. 2013 Aug 19;54(8):5629-37.

Meza-Rios A, Navarro-Partida J, Armendariz-Borunda J, Santos A. Therapies Based on Nanoparticles for Eye Drug Delivery. Ophthalmol Ther. 2020 Sep;9(3):1-14.

Ribeiro A, Veiga F, Santos D, Torres-Labandeira JJ, Concheiro A, Alvarez-Lorenzo C. Bioinspired imprinted PHEMA-hydrogels for ocular delivery of carbonic anhydrase inhibitor drugs. Biomacromolecules. 2011 Mar 14;12(3):701-9.

Hao X, Han Z, Zhu C. Topical composition for treating diabetic cataracts: a patent evaluation (WO2015026380A1). Expert Opin Ther Pat. 2016 Jun;26(6):731-5.

Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008 Oct;146(4):554-60. doi: 10.1016/j.ajo.2008.04.036.

Yüksel B, Karti Ö, Kusbeci T. Topical nepafenac for prevention of post-cataracts surgery macular edema in diabetic patients: patient selection, and perspectives. Clin Ophthalmol. 2017 Dec 11;11:2183-90.

Julius A, Hopper W. A non-invasive, multi-target approach to treat diabetic retinopathy. Biomed Pharmacother. 2019 Jan;109:708-15.

Manni G. Can Treatment With Citicoline Eyedrops Reduce Progression in Glaucoma? The Results of a Randomized Placebo-controlled Clinical Trial. J Glaucoma. 2020 Jul;29(7):513-20.

Published

08-10-2021

How to Cite

MANORMA, MAZUMDER, R., RANI, A., BUDHORI, R., & KAUSHIK, A. (2021). CURRENT MEASURES AGAINST OPHTHALMIC COMPLICATIONS OF DIABETES MELLITUS - A SHORT REVIEW. International Journal of Applied Pharmaceutics, 13(6). https://doi.org/10.22159/ijap.2021v13i6.42876

Issue

Section

Review Article(s)